AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $285.15, with a market capitalization of 503.89B. The stock trades at a price-to-earnings (P/E) ratio of 80.52 and offers a dividend yield of 2.40%.
On 2026-10-22, AbbVie(ABBV) stock traded between a low of $276.50 and a high of $288.32. Shares are currently priced at $285.15, which is +3.1% above the low and -1.1% below the high.
AbbVie(ABBV) shares are trading with a volume of 3.68M, against a daily average of 5.46M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
ABBV News
AbbVie (NYSE:ABBV) reported positive topline Phase 3 INTREPID results for lutikizumab in moderate to severe hidradenitis suppurativa. The INTREPID program incl...
AbbVie Inc. (NYSE:ABBV) on Thursday shared topline results from its Phase 3 INTREPID study evaluating lutikizumab in adults and adolescents with moderate to sev...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie is running a mid-stage study to test a new injection, gemibotulinumtoxinA (AGN-151607...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie (ABBV) announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-vari...
Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the sto...
Goldman Sachs raised the firm’s price target on AbbVie (ABBV) to $294 from $258 and keeps a Neutral rating on the shares. AbbVie’s recent outperformance reflect...
AbbVie (ABBV Quick QuoteABBV - Free Report) closed at $284.80 in the latest trading session, marking a -1.48% move from the prior day. This move lagged th...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has stopped a Phase 1b study called “A Study to Assess the Adverse Events and...
AbbVie: Consistent Upward Revenue Trajectory AbbVie (ABBV +2.26%) primarily generates its revenue by developing advanced therapies across immunology, oncology,...
Investing Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead Social Security raises are locked to a government formula, but a growing numbe...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.